Reuters logo
BRIEF-Europea's CHMP recommends Merck's Keytruda for lung cancer treatment
December 16, 2016 / 12:35 PM / 9 months ago

BRIEF-Europea's CHMP recommends Merck's Keytruda for lung cancer treatment

Dec 16 (Reuters) - Merck & Co Inc

* European medicines agency’s chmp recommends Merck’s Keytruda (pembrolizumab) for the first-line treatment of patients with metastatic non-small cell lung cancer (nsclc) whose tumors have high pd-l1 expression with no egfr or alk positive

* Merck & Co Inc - final decision regarding keytruda by european commission is expected in q1 of 2017 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below